Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Finished Goods (2016 - 2025)

Historic Finished Goods for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $88.3 million.

  • Orthofix Medical's Finished Goods fell 2489.11% to $88.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.3 million, marking a year-over-year decrease of 2489.11%. This contributed to the annual value of $105.4 million for FY2024, which is 2489.13% down from last year.
  • Latest data reveals that Orthofix Medical reported Finished Goods of $88.3 million as of Q3 2025, which was down 2489.11% from $85.0 million recorded in Q2 2025.
  • Orthofix Medical's 5-year Finished Goods high stood at $140.7 million for Q3 2023, and its period low was $14.7 million during Q2 2021.
  • Its 5-year average for Finished Goods is $84.0 million, with a median of $88.3 million in 2025.
  • As far as peak fluctuations go, Orthofix Medical's Finished Goods tumbled by 4891.41% in 2021, and later surged by 47149.02% in 2023.
  • Over the past 5 years, Orthofix Medical's Finished Goods (Quarter) stood at $58.3 million in 2021, then increased by 9.58% to $63.9 million in 2022, then soared by 119.6% to $140.3 million in 2023, then decreased by 24.89% to $105.4 million in 2024, then decreased by 16.19% to $88.3 million in 2025.
  • Its Finished Goods was $88.3 million in Q3 2025, compared to $85.0 million in Q2 2025 and $91.6 million in Q1 2025.